Accessibility Menu
TuHURA Biosciences logo

TuHURA Biosciences(NASDAQ) HURA

Market Cap$136.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-66%
5 Year-100%
1 Year-11%
1 Month-12%
$2.14
-1.38%
-0.03Today
TuHURA Biosciences last closing stock price
MetricPriceDate
Last closeUSD 2.142026-08-03
TuHURA Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.17%USD 2.212026-07-27
1 month-12.3%USD 2.442026-07-02
3 month-7.76%USD 2.322026-05-05
Year to date+182.81%USD 0.762025-12-31
1 year-10.83%USD 2.402025-08-01
3 year-97%USD 71.232023-08-04
5 year-99.83%USD 1,295.002021-08-04
Since inception-66.03%USD 6.302024-10-18

TuHURA Biosciences Financials at a Glance

Market Cap

$136.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$30.93M

EPS (TTM)

-$0.60

P/E Ratio

-3.55

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$2.14

Volume

1,500

Open

$2.20

Previous Close

$2.14

Daily Range

$2.12 - $2.22

52-Week Range

$0.41 - $3.90

Estimated Earnings Date

Aug 13, 2026

HURA News

Foolcom-Featured.png

TuHURA R&D Jumps 75% in Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TuHURA Biosciences

TuHURA develops medicines to help the immune system fight cancer. Its main products aim to help patients whose cancers resist current treatments. The company focuses on therapies for people with advanced or hard-to-treat cancers.

Lab Coats & Cancer Fighters: What TuHURA Makes

  • IFx-2.0 Platform: Lead drug in late-stage testing, helps immune cells recognize and attack cancer; targets patients with advanced skin cancer. (0% of revenue)
  • TBS-2025 Antibody: Blocks a protein that helps cancer hide from the immune system; aimed at blood cancer patients. (0% of revenue)
  • DOR-Targeted ADCs: Experimental drugs designed to deliver immune effectors to immune-suppressing cells in tumors; for both solid and blood cancers. (0% of revenue)
  • Paused IFx-3.0: mRNA-based immune therapy, development on hold pending results from IFx-2.0. (0% of revenue)
  • Research Services: All activities are research-focused; no commercial products or sales yet. (0% of revenue)

Growth Spurts & Science Sprints: How TuHURA Expands

  • Acquired Kineta in June 2025, adding new antibody therapies to its pipeline.
  • Launched Phase 3 trial for IFx-2.0 in June 2025 for advanced skin cancer.
  • Expanded pipeline in 2025 to include DOR-targeted antibody-drug conjugates for resistant cancers.
  • Formed manufacturing partnerships with Samsung Biologics and contract research organizations in 2025.
  • Increased intellectual property portfolio to 33 patents across 13 countries by end of 2025.

What Makes TuHURA Stand Out in the Crowd

TuHURA uses unique science to help the immune system spot and attack cancer cells. Its approach targets patients who do not respond to standard treatments. The company’s focus on new drug types and partnerships supports its research-driven model.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $30.1 million in 2025, up 38.7% from 2024.
  • Research and development expenses were $20.5 million in 2025, up 54.1% from 2024.
  • Cash and cash equivalents were $3.6 million at year-end 2025, down 71.7% from 2024.

Bottom Line

TuHURA remains a research-focused biotech with no product sales and rising costs. Its future depends on clinical trial success and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

22

CEO

James A. Bianco, MD

Website

www.tuhurabio.com

Headquarters

Tampa, FL 33612, US

HURA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-153.99%

Return on Capital

-146.98%

Return on Assets

-104.13%

Earnings Yield

-28.17%

Dividend Yield

0.00%

Payout Ratio

-0.03%

Stock Overview

Market Cap

$136.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.68M

Volume

1.50K

Avg. Volume

533.12K

Financials (TTM)

Gross Profit

-$23.47K

Operating Income

-$32.31M

EBITDA

-$30.19M

Operating Cash Flow

-$27.30M

Capital Expenditure

-$82.26K

Free Cash Flow

-$27.39M

Cash & ST Invst.

$6.30M

Total Debt

$456.93K

TuHURA Biosciences Performance Analysis

TuHURA Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
TuHURA Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
TuHURA Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -324.48-64.1%
20242024-06-30USD -11.29-96.5%
20242024-12-31USD -1.21-96.5%
20252025-12-31USD -0.63-48.3%
TuHURA Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-42.5%
Q32025-09-3034.5%
Q42025-12-317.1%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$23.47K

N/A

Gross Margin

0.00%

N/A

Market Cap

$136.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.19M

N/A

Employees

22

N/A

Net Income

-$7.54M

-13.1%

EBITDA

-$7.49M

-12.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.30M

+1.3%

Total Debt

$456.93K

+177.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$250.08K

N/A

Short Term Debt

$206.85K

+25.7%

Return on Assets

-1.04%

N/A

Return on Invested Capital

-1.37%

N/A

Free Cash Flow

-$4.46M

+6.7%

Operating Cash Flow

-$4.41M

+6.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SEERSeer, Inc.
$2.24+0.90%
ABOSAcumen Pharmaceuticals, Inc.
$2.18+1.40%
CGTXCognition Therapeutics, Inc.
$0.89+0.21%
SPROSpero Therapeutics, Inc.
$1.15-1.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
PLTRPalantir Technologies
$125.65+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%

Questions About HURA

What is the current price of TuHURA Biosciences?

TuHURA Biosciences is trading at $2.14 per share.

What is the 52-week range for TuHURA Biosciences?

Over the past 52 weeks, TuHURA Biosciences has traded between $0.41 and $3.90.

How much debt does TuHURA Biosciences have?

As of the most recent reporting period, TuHURA Biosciences reported total debt of $456.93K.

How much cash does TuHURA Biosciences have on hand?

TuHURA Biosciences reported $6.30M in cash and cash equivalents in its most recent financial results.

What is TuHURA Biosciences’s dividend yield?

TuHURA Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services